DaVita (DVA) Misses Q4 EPS

DaVita (NYSE: DVA) reported Q4 EPS of $1.67, versus the analyst estimate of $1.91. Revenue for the quarter came in at $2.91 billion versus the consensus estimate of $2.93 billion.

"Throughout the pandemic, including the recent surge in the number of COVID-19 cases across the United States, our teammates continue to respond with a focus on the health and safety of 240,000 patients receiving high quality, life-sustaining care," said Javier Rodriguez, CEO of DaVita. "Over the past six weeks, we have begun providing vaccinations to our front-line caregivers, and we are now beginning the process of providing COVID-19 vaccinations to our patients."

For earnings history and earnings-related data on DaVita (DVA) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• Spotify (SPOT) jumps 10% as Q1 revenue, gross margins beat Street's estimates
• Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q1 EPS by 11c; raises guidance